All In Biotech

Drug Trial Radar · NCT02513940

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

Last checked: Nov 19, 2026Latest source record: Aug 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

14

Actual

Start

May 2016

Primary completion

Oct 19, 2017

Study completion Oct 19, 2017

Sponsor

Lead sponsor
Indiana UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
American Heart Association; Purdue University
First posted
Aug 3, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Male only, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Torsades de pointes (TdP) is a potentially fatal ventricular arrhythmia associated with corrected QT (QTc) interval prolongation. More than 50 commonly used drugs available on the US market may cause QTc interval prolongation and TdP. While TdP occurs more commonly in women, 33-45% of all cases of TdP have occurred in men. Older age is a risk factor for drug-induced TdP in men, possibly due to declining serum testosterone concentrations. Available evidence shows an inverse relationship between QTc intervals and serum testosterone concentrations. In addition, experimental data, including those from the investigators' laboratory, suggest that both exogenous testosterone or progesterone administration may be protective against prolongation of ventricular repolarization and TdP. Specific Aim: Establish the influence of transdermal testosterone administration and oral progesterone administration as preventive methods by which to diminish the degree of drug-induced QT interval prolongation in men 65 years of age or older. Hypothesis: Transdermal testosterone administration and oral progesterone administration both effectively attenuate drug-induced QT interval response in older men. To test this hypothesis, transdermal testosterone, oral progesterone or placebo will be administered in a 3-way crossover study to men 65 years of age or older. QTc interval response to low-dose ibutilide will be assessed. The primary endpoints will be Fridericia-corrected QT interval (QTF) response to ibutilide, in the presence and absence of testosterone, and in the presence or absence of progesterone: 1) Effect on pre-ibutilide QTF, 2) Effect on maximum post-ibutilide QTF, 3) Effect on % change in post-ibutilide QTF, and 2) Area under the QTF interval-time curves.

Conditions

  • Long QT Syndrome

Interventions

  • TestosteroneDrug

    Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days

  • ProgesteroneDrug

    Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

  • PlaceboDrug

    Subjects will receive placebo transdermal gel and placebo (lactose) capsules

  • IbutilideDrug

    Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF)Time frame: Following 7 days of testosterone, progesterone or placebo
  2. Maximum QTF Following Ibutilide 0.003 mg/kgTime frame: Within 8 hours following ibutilide administration
  3. Maximum Percent Change From Pretreatment Value in QTF Following Ibutilide 0.003 mg/kgTime frame: Within 8 hours of ibutilide administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Indiana University

    Indianapolis, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.